News | November 23, 2008

Endologix Announces Favorable Powerlink XL Clinical Trial Results

November 24, 2008 - Endologix Inc. today said results from its Powerlink XL system for the minimally invasive treatment of abdominal aortic aneurysms (AAA) prospective, multi-center clinical trial met the primary endpoint of one-year post-procedure freedom from Type I proximal endoleak.

Additionally, no stent graft distal migration was observed in any study patient at one year following the procedure, the company said. The trial was conducted under an investigational device exemption (IDE) approved by the FDA and the Powerlink XL is currently being commercially launched in the U.S.

Additional one-year follow-up results for the Powerlink XL study include zero aneurysm-related mortality, aneurysm rupture, or conversion to open repair. Independent Core Lab evaluation reported no ePTFE graft disruptions, stent fractures, or Type III or IV endoleaks. The study also showed stable or significantly reduced aneurysm sac diameter in 96 percent of patients.

Data from the Powerlink XL trial were presented today at the 35th Annual VEITHsymposium by the trial’s principal investigator professor William D. Jordan, Jr., M.D. , chief of vascular surgery, UAB Hospital, Birmingham, AL. Dr. Jordan reviewed results of this approach to endovascular treatment of patients with aortic necks up to 32mm in diameter. All patients received the Powerlink bifurcated device via anatomical fixation at the aortic bifurcation, as well as the Powerlink XL proximal extension to achieve proximal seal.

“These impressive data are consistent with the positive results reported by other clinicians who have used the Powerlink System to treat patients with aortic necks up to 26mm,” Dr. Jordan said. “Importantly, for the first time, we were able to demonstrate in a designed study the benefit of an AAA endograft in achieving secure fixation at the bifurcation with proximal seal in a patient group with large aortic necks.”

He said the results are significant given the relatively high prevalence of hostile neck anatomy with severe thrombus and/or a reverse taper, which occurred in more than 80 percent of patients.

For more information:

Related Content

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.
FDA Concerned About Increase in stent graft Endovascular Type III Leaks
News | Stent Grafts | October 09, 2017
October 9, 2017 — The U.S.
Gore Announces First-in-Human Use of Gore TAG Conformable Thoracic Stent Graft
News | Stent Grafts | July 17, 2017
W. L. Gore & Associates Inc. announced the first patient implant of the Gore TAG Conformable Thoracic Stent Graft...
News | Stent Grafts | April 06, 2017
Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer...
Gore, Viabahn VBX Balloon Expandable Endoprosthesis, stent graft, iliac artery, FDA approval
Technology | Stent Grafts | January 31, 2017
W. L. Gore & Associates (Gore) announced that the Gore Viabahn VBX Balloon Expandable Endoprosthesis (VBX Stent...
Overlay Init